Asian Journal of Research in Dermatological Science
https://journalajrdes.com/index.php/AJRDES
<p style="text-align: justify;"><strong>Asian Journal of Research in Dermatological Science</strong> aims to publish high-quality papers (<a href="/index.php/AJRDES/general-guideline-for-authors">Click here for Types of paper</a>) in all aspects of ‘Dermatological Science’. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p>Asian Journal of Research in Dermatological Scienceen-USAsian Journal of Research in Dermatological ScienceDermatological Emergencies of a University Hospital Center of Rabat, Morocco
https://journalajrdes.com/index.php/AJRDES/article/view/99
<p><strong>Introduction:</strong> Dermatological emergency is defined as any acute dermatological disorder that develops and worsens in less than 5 days. </p> <p><strong>Aims of Study:</strong> The aim of our study is to identify the main dermatological emergencies consultations, establish a demographic and clinical profile of the reasons for dermatological consultations, and review the various diagnostic and therapeutic difficulties encountered by interns and/or residents.</p> <p><strong>Materials and Methods: </strong>We conducted a prospective study in the dermatology department of the Ibn Sina University Hospital in Rabat between June 2022, and May2023. Excel and Statistical Package for the Social Sciences (SPSS Inc., version 15.0 for Windows) were used for data entry andanalysis. <strong>Results:</strong> 1,321 urgent dermatology consultations were received during this period. The sex ratio was 0.89, and the average age was 45.6 years (01months-95years). The reasons for consultation were: infectious pathologies in 47% (Erysipelas in the lead), inflammatory pathologies in 24%, toxidermia in 7%, autoimmune bullous dermatosis in 4%, tumor pathologies in 3%, and others in 15% of cases. 79 cases (5,9%) were hospitalized as emergencies and while the others (94,1%) only needed an ambulatory care.</p> <p><strong>Conclusion: </strong>The pathologies encountered in dermatological emergencies are very diverse dominated by infectious diseases. However, the majority of patients do not require an emergency consultation.</p>Amani Fliti Meryem Elomari Alaoui Mariame Meziane Nadia Ismaili Laila Benzekri Karima Senouci
Copyright (c) 2024 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2024-03-182024-03-181013The Use of Secukinumab in Psoriatic Patients: A Single Center Study in Morocco
https://journalajrdes.com/index.php/AJRDES/article/view/100
<p><strong>Introduction</strong><strong>:</strong> Psoriasis is an immune cell-mediated inflammatory skin disease, characterized by the formation of scaly, indurated, erythematous plaques<strong>. </strong>Psoriasis comorbidities and symptoms affect the choice of treatments. Secukinumab is a fully human monoclonal anti-body that selectively neutralizes IL-17A and has proven to be effective in the treatment of multiple manifestations of psoriatic disease.</p> <p><strong>Materials and Methods</strong><strong>:</strong> In this prospective descriptive study of 13 patients with moderate to severe psoriasis in the Department of Dermatology at Ibn Sina University Hospital in Rabat between 2022 and 2024, we focus on the treatment of psoriasis with Secukinumab. All our patients received more than 6 injections of Secukinumab. Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, and percentage of patients achieving PASI 75/90/100, at weeks 4 and 16.</p> <p><strong>Results</strong><strong>:</strong> In this study, 13 patients with severe psoriasis with a PASI>10 were included. The mean age at diagnosis was 44.7 years and the mean duration of the disease before diagnosis was 5 years. All our patients received Secukinumab following this protocol (subcutaneous injection of 300mg at weeks 0,1,2,3 and 4, followed by 300mg every 4 weeks) and the PASI 75, PASI 90, PASI 100 was evaluated respectively.</p> <p>At week 4, 69.2% of patients still on Secukinumab had experienced at least a 50% reduction in PASI (PASI 50) from baseline. At week 16, the proportions of patients achieving PASI 75, PASI 90, and PASI 100 were: 23,1%, 30,7%, (46,2%) respectively.</p> <p>Adverse events possibly relevant to Secukinumab therapy were not reported in our patients</p> <p><strong>Conclusion</strong><strong>:</strong> To improve the quality of life of psoriatic patients, the choice of available treatments is now increasing. Secukinumab showed sustained effectiveness and favorable safety profile in patients with moderate to severe psoriasis in our patients.</p>Meryem Elomari AlaouiAmani Fliti Mariame Meziane Nadia Ismaili Laila Benzekri Karima Senouci
Copyright (c) 2024 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2024-03-222024-03-221418Determination of Dermatology Life Quality Index Criteria in Libyan Pemphigus Patients
https://journalajrdes.com/index.php/AJRDES/article/view/98
<p><strong>Introduction:</strong> The term "pemphigus" describes a group of uncommon autoimmune dermatoses of the mucocutaneous membranes caused by acantholysis, or the breakdown of cell-to-cell adhesion, which can result in the production of potentially fatal bullae and erosion. Based on their unique clinical characteristics and pathogenesis, several subtypes of pemphigus illness have been discovered. These subtypes include paraneoplastic pemphigus (PNP), IgA pemphigus, pemphigus vulgaris (PV), and pemphigus foliaceus (PF).</p> <p><strong>Aim of the Study: </strong>To measure the Dermatology Life Quality Index (DLQI) in Libyan pemphigus patients and assess the impact of the disease on their lives.</p> <p><strong>Materials and Methods: </strong>In this descriptive study, 25 patients with pemphigus attending Bullous Clinic, dermatology department, Jumhoria Hospital, Benghazi, Libya, over one year from January to December 2021, were enrolled. All patients were registered in the clinic, and the diagnosis of pemphigus was confirmed by histopathology. For every patient, the DLQI score was measured by filling out the questionnaire.</p> <p><strong>Results: </strong>Of the 25 patients with pemphigus included in this study, 5 patients (20%) were male and 20 patients (80%) were female. The age ranged from 30 to 72 years, and the mean age was 43.64 years. The duration of the disease ranged from 1 to 408 months (mean: 83.12 months). Pemphigus folaiceous was encountered in 13 patients (52%). Concerning disease severity, 44% of cases presented with a severe illness. In 15 patients (60%), mucous membranes were not involved. Eight patients (32%) were treated with steroids (Prednisolone) and cytotoxic (Azathioprine) drugs. The mean DLQI scores for pemphigus vulgaris were 12.67 and for pemphigus folaiceous were 10.31. Dermatology Qualify Life Index (DLQI) scores showed a large effect on life quality in 56% of the study cases and a moderate effect in 32% of them.</p> <p><strong>Conclusion:</strong> Pemphigus has a substantial impact on Libyan patients' DLQI scores; individuals receiving systemic combination treatment were shown to have lower scores.</p>Hussein Osman Tarik Enaairi Ghait Alsdae Gamal Duweb
Copyright (c) 2024 Osman et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2024-02-022024-02-0219